RecoveryClinical Trials
Larazotide
Also known as: AT-1001 · Larazotide acetate
A tight-junction regulator and zonulin antagonist developed for celiac disease, physically sealing the 'leaky gut' at its mechanical root cause.
Reviewed by Dr. Sarah Mitchell, PharmD, BCPS
Lead Researcher · 12+ years in peptide therapeutics
Half-Life
~4–6 hours
Typical Dose
0.5 mg three times daily
Administration
Oral
Mechanism of Action
Blocks zonulin-mediated opening of intestinal tight junctions, preventing gluten-induced paracellular permeability increase.
Key Research Areas
gutceliacleaky guttight junctionszonulin
Frequently Asked Questions
What is Larazotide?▾
A tight-junction regulator and zonulin antagonist developed for celiac disease, physically sealing the 'leaky gut' at its mechanical root cause.
How does Larazotide work?▾
Blocks zonulin-mediated opening of intestinal tight junctions, preventing gluten-induced paracellular permeability increase.
What is the recommended dosage for Larazotide?▾
The typical research dosage is 0.5 mg three times daily, administered via Oral. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Larazotide?▾
The half-life of Larazotide is approximately ~4–6 hours. This affects dosing frequency and timing in research protocols.
Is Larazotide FDA approved?▾
Larazotide is currently classified as "Clinical Trials" and is not FDA approved for general use. It is available for research purposes or through compounding pharmacies depending on your jurisdiction.
Research Disclaimer
The information provided about Larazotide is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.